Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
Xue
C B
CB
The DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, Delaware 19880-0500, USA.
He
X
X
Roderick
J
J
DeGrado
W F
WF
Cherney
R J
RJ
Hardman
K D
KD
Nelson
D J
DJ
Copeland
R A
RA
Jaffee
B D
BD
Decicco
C P
CP
D018360:Crystallography, X-Ray; D006801:Humans; D006877:Hydroxamic Acids / Q000097:blood / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D007769:Lactams / Q000097:blood / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000097:blood / Q000494:pharmacology; D008213:Lymphocyte Activation; D020781:Matrix Metalloproteinase 1; D020780:Matrix Metalloproteinase 9; D061965:Matrix Metalloproteinase Inhibitors; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000097:blood; D008958:Models, Molecular; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D006877:Hydroxamic Acids; D007769:Lactams; D008070:Lipopolysaccharides; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; C112417:SC 903; C112416:SE 205; D014409:Tumor Necrosis Factor-alpha; D008666:Metalloendopeptidases; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1